1. Home
  2. UBX vs ELEV Comparison

UBX vs ELEV Comparison

Compare UBX & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UBX
  • ELEV
  • Stock Information
  • Founded
  • UBX 2009
  • ELEV 2019
  • Country
  • UBX United States
  • ELEV United States
  • Employees
  • UBX N/A
  • ELEV N/A
  • Industry
  • UBX Biotechnology: Pharmaceutical Preparations
  • ELEV Biotechnology: Pharmaceutical Preparations
  • Sector
  • UBX Health Care
  • ELEV Health Care
  • Exchange
  • UBX Nasdaq
  • ELEV Nasdaq
  • Market Cap
  • UBX 18.4M
  • ELEV 20.0M
  • IPO Year
  • UBX 2018
  • ELEV 2021
  • Fundamental
  • Price
  • UBX $0.75
  • ELEV $0.34
  • Analyst Decision
  • UBX Strong Buy
  • ELEV Buy
  • Analyst Count
  • UBX 3
  • ELEV 6
  • Target Price
  • UBX $5.33
  • ELEV $2.94
  • AVG Volume (30 Days)
  • UBX 141.5K
  • ELEV 975.2K
  • Earning Date
  • UBX 04-22-2025
  • ELEV 05-23-2025
  • Dividend Yield
  • UBX N/A
  • ELEV N/A
  • EPS Growth
  • UBX N/A
  • ELEV N/A
  • EPS
  • UBX N/A
  • ELEV N/A
  • Revenue
  • UBX N/A
  • ELEV N/A
  • Revenue This Year
  • UBX N/A
  • ELEV N/A
  • Revenue Next Year
  • UBX N/A
  • ELEV N/A
  • P/E Ratio
  • UBX N/A
  • ELEV N/A
  • Revenue Growth
  • UBX N/A
  • ELEV N/A
  • 52 Week Low
  • UBX $0.85
  • ELEV $0.22
  • 52 Week High
  • UBX $3.10
  • ELEV $4.33
  • Technical
  • Relative Strength Index (RSI)
  • UBX 28.49
  • ELEV 48.18
  • Support Level
  • UBX $0.70
  • ELEV $0.33
  • Resistance Level
  • UBX $0.95
  • ELEV $0.37
  • Average True Range (ATR)
  • UBX 0.10
  • ELEV 0.03
  • MACD
  • UBX -0.01
  • ELEV 0.00
  • Stochastic Oscillator
  • UBX 8.49
  • ELEV 25.54

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

About ELEV Elevation Oncology Inc. Common stock

Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.

Share on Social Networks: